Once adults reach age 65, the threshold age for the onset of Alzheimer’s disease, the extent of their genetic risk may outweigh age as a predictor of whether they will develop the fatal brain disorder, a new study suggests.
Though age constitutes one-third of total risk for developing Alzheimer’s disease by age 85, the study found that for adults 65 and older, genetic risk as determined by a polygenic risk score was more predictive than age of who would develop the brain disorder.
A study published recently in the journal Scientific Reports, is the first to construct machine learning models with genetic risk scores, non-genetic information and electronic health record data from nearly half a million individuals to rank risk factors in order of how strong their association is with eventual development of Alzheimer’s disease.
Researchers used the models to rank predictive risk factors for two populations from the UK Biobank: White individuals aged 40 and older, and a subset of those adults who were 65 or older. Their results showed that age — which constitutes one-third of total risk by age 85, according to the Alzheimer’s Association — was the biggest risk factor for Alzheimer’s in the entire population, but for the older adults, genetic risk as determined by a polygenic risk score was more predictive.
“We all know Alzheimer’s disease is a later-onset disease, so we know age is an important risk factor. But when we consider risk only for people age 65 or older, then genetic information captured by a polygenic risk score ranks higher than age,” said lead study author Xiaoyi Raymond Gao, associate professor of ophthalmology and visual sciences and of biomedical informatics in The Ohio State University College of Medicine. “That means it’s really important to consider genetic information when we work on Alzheimer’s disease.”
A low household income also emerged as an important risk factor, ranking either third or fourth after the effects of age and genetics. “The finding related to income is very, very interesting,” said Gao, also a member of Ohio State’s Division of Human Genetics faculty, whose lab uses biomedical big data and artificial intelligence to study the genetics behind Alzheimer’s and ocular diseases. “We all want to have a healthy life, and income can be such an important factor to decide what you can afford to eat, where you can afford to live, education level, access to care – and all of these possibly contribute to Alzheimer’s disease.”
Of the 457,936 UK Biobank participants in the sample, 2,177 individuals had developed Alzheimer’s disease and 455,759 had not, and 88,309 were 65 or older. A few non-genetic risk factors that differed between people with and without Alzheimer’s disease (AD) stood out: Results showed that in people with AD, higher systolic and lower diastolic blood pressure were more common, diabetes was more prevalent, household income and education were lower, and recent falls, hearing difficulty and a mother’s history of having AD were higher.
Top-20 Risk Factors for Developing Alzheimer’s
The top-20 list of risk factors for the full sample of adults also included diagnoses of high blood pressure, urinary tract infection, depressive episodes, fainting, unspecified chest pain, disorientation and abnormal weight loss. Other risk factors in the top 20 for people 65 and older included high cholesterol and gait abnormalities. These findings showed the power of adding condition codes from electronic health records to the models.
“Machine learning can explore relationships among all of those features, or variables, pick the important features and rank certain features at the top that contribute much more to Alzheimer’s disease risk than the rest of the features,” Gao said. “Typically, it’s not good to be highly obese, but we also see here that a lower body mass index is not good. High blood pressure is typically not good, but here we see lower diastolic blood pressure is not good. The models revealed some interesting patterns.”
Building the models was a two-step process. The team first conducted genome-wide association studies using data from the Alzheimer’s Disease Genetics Consortium to identify genetic variants linked to overall risk of developing Alzheimer’s disease and to development of the disease after a specific age. The separate collections of variants were used to establish two polygenic risk scores, which aggregate genetic effects across the genome into a single measure of risk for each individual.
Those scores were applied to DNA data from the UK Biobank participants and combined with biobank information on conventional risk factors such as sex, education, body mass index and blood pressure, and more than 11,000 electronic health record condition codes that had been cited in individuals’ records.
Date: 08.12.2025
Naturally, we always handle your personal data responsibly. Any personal data we receive from you is processed in accordance with applicable data protection legislation. For detailed information please see our privacy policy.
Consent to the use of data for promotional purposes
I hereby consent to Vogel Communications Group GmbH & Co. KG, Max-Planck-Str. 7-9, 97082 Würzburg including any affiliated companies according to §§ 15 et seq. AktG (hereafter: Vogel Communications Group) using my e-mail address to send editorial newsletters. A list of all affiliated companies can be found here
Newsletter content may include all products and services of any companies mentioned above, including for example specialist journals and books, events and fairs as well as event-related products and services, print and digital media offers and services such as additional (editorial) newsletters, raffles, lead campaigns, market research both online and offline, specialist webportals and e-learning offers. In case my personal telephone number has also been collected, it may be used for offers of aforementioned products, for services of the companies mentioned above, and market research purposes.
Additionally, my consent also includes the processing of my email address and telephone number for data matching for marketing purposes with select advertising partners such as LinkedIn, Google, and Meta. For this, Vogel Communications Group may transmit said data in hashed form to the advertising partners who then use said data to determine whether I am also a member of the mentioned advertising partner portals. Vogel Communications Group uses this feature for the purposes of re-targeting (up-selling, cross-selling, and customer loyalty), generating so-called look-alike audiences for acquisition of new customers, and as basis for exclusion for on-going advertising campaigns. Further information can be found in section “data matching for marketing purposes”.
In case I access protected data on Internet portals of Vogel Communications Group including any affiliated companies according to §§ 15 et seq. AktG, I need to provide further data in order to register for the access to such content. In return for this free access to editorial content, my data may be used in accordance with this consent for the purposes stated here. This does not apply to data matching for marketing purposes.
Right of revocation
I understand that I can revoke my consent at will. My revocation does not change the lawfulness of data processing that was conducted based on my consent leading up to my revocation. One option to declare my revocation is to use the contact form found at https://contact.vogel.de. In case I no longer wish to receive certain newsletters, I have subscribed to, I can also click on the unsubscribe link included at the end of a newsletter. Further information regarding my right of revocation and the implementation of it as well as the consequences of my revocation can be found in the data protection declaration, section editorial newsletter.
The team also used an algorithm in interpreting the model’s output to ensure risk factor variables were weighted objectively in the analysis. We are born with our genetic risk for disease already established, but information about how other health and socioeconomic factors affect our risk for Alzheimer’s — as well as glaucoma, which Gao also studies — gives us power to take preventive measures, he said.
“If people know more about risk factors, they can possibly adjust their lifestyle. For both Alzheimer’s and glaucoma, there is no cure, so prevention can help a lot,” Gao said. “I also hope constructing models to make these predictions could help with drug development and effective and low-cost screening programs.”
References: Explainable machine learning aggregates polygenic risk scores and electronic health records for Alzheimer’s disease prediction; Scientific Reports; DOI:10.1038/s41598-023-27551-1